10 Stocks of Top-Performing Mutual Funds in 2012

5. Arctic Cat (ACAT)

Company profile: Arctic Cat, with a market value of $467 million, designs, engineers, manufactures, and markets snowmobiles and all-terrain vehicles (ATVs) under the Arctic Cat brand name.

Investor takeaway: Its shares are up 42% this year and have a three-year, average annual return of 100%. Analysts give its shares two "buy" ratings, two "buy/holds," and two "holds," according to a survey of analysts by S&P. Analysts estimate it will earn $2.73 per share this fiscal year and rise 24% to $3.38 next year.

4. Sears Holdings (SHLD)

Company profile: Sears Holdings, with a market value of $5.6 billion, is the parent company of Sears, Sears Canada and Kmart stores. It is the fourth-largest broadline retailer in the U.S.

Investor takeaway: Its shares are up 59% this year but have a three-year, average annual decline of 9.8%. Analysts give its shares two "hold," ratings, three "weak holds," and one "sell," according to a survey of analysts by S&P. Analysts estimate it will lose $2.66 in its fiscal 2013 and lose $2.57 in the following year. It is in the process of downsizing and refocusing its efforts, with plans to close over 173 underperforming stores this year.

3. Monster Beverage (MNST)

Company profile: Monster, with a market value of $13 billion, develops, markets, and sells a variety of nonalcoholic beverages, including energy drinks, natural sodas, and fruit juices. Its Monster Energy Drink is the second-largest selling energy drink in the U.S.

Investor takeaway: Its shares are up 62% this year and have a three-year, average annual return of 69%. Analysts give its shares four "buy" ratings, two "buy/holds," four "holds," and one "weak hold," according to a survey of analysts by S&P. Analysts estimate it will earn $2.04 per share this year and $2.51 next year.

2. American Vanguard Corp. (AVD)

Company profile: American Vanguard, with a market value of $736 million, is a specialty chemical manufacturer with a focus on the agricultural and commercial markets.

Investor takeaway: Its shares are up 92% this year and have a three-year, average annual return of 34%. Analysts give its shares one "buy" rating, one "buy/hold," and one "hold," according to a survey of analysts by S&P.

Analysts estimate it will earn $1.06 per share this year and that earnings will grow by 25% to $1.32 next year.

1. Regeneron Pharmaceuticals (REGN)

Company profile: Regeneron, with a market value of $11 billion, is a biotech firm that develops, and commercializes drugs that fight inflammation, cancer, and eye disease.

Investor takeaway: Its shares are up 102% this year and have a three-year, average annual return of 90%. Analysts give its shares seven "buy" ratings, two "buy/holds," and seven "holds," according to a survey of analysts by S&P.

Analysts estimate it will earn $1.25 per share this year and that earnings will grow 105% to $2.56 in 2013.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

« First ‹ Previous 1 2 3